Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.
COVID-19
Multiple sclerosis
SARS-CoV2
Vaccination
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
27
04
2021
revised:
04
05
2021
accepted:
10
05
2021
pubmed:
29
5
2021
medline:
7
7
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
Some people with multiple sclerosis (pwMS) are at increased risk of severe Coronavirus disease 19 (COVID-19) and should be rapidly vaccinated. However, vaccine supplies are limited, and there are concerns about side-effects, particularly with the ChAdOx1nCoV-19 (AstraZeneca) vaccine. To report our first experience of pwMS receiving the AstraZeneca vaccine. Service evaluation. pwMS using the MS service at Barts Health NHS Trust were sent questionnaires to report symptoms following vaccination. Thirty-three responses were returned, 29/33 pwMS received a first dose of AstraZeneca vaccine, the remaining four received a first dose of BioNTech/Pfizer vaccine. All but two patients (94%) reported any symptoms including a sore arm (70%), flu-like symptoms (64%), fever (21%), fatigue (27%), and headache (21%). In more than 2/3 patients, symptoms lasted up to 48 hours, and with the exception of two pwMS reporting symptom duration of 10 and 12 days, respectively, symptoms in the remainder resolved within seven days. No severe adverse effects occurred. pwMS report transient symptoms following AstraZeneca vaccination, characteristics of which were similar to those reported in the non-MS population. Symptoms may be more pronounced in pwMS due to the temperature-dependent delay in impulse propagation (Uhthoff's phenomenon) due to demyelination.
Sections du résumé
BACKGROUND
BACKGROUND
Some people with multiple sclerosis (pwMS) are at increased risk of severe Coronavirus disease 19 (COVID-19) and should be rapidly vaccinated. However, vaccine supplies are limited, and there are concerns about side-effects, particularly with the ChAdOx1nCoV-19 (AstraZeneca) vaccine.
OBJECTIVES
OBJECTIVE
To report our first experience of pwMS receiving the AstraZeneca vaccine.
METHODS
METHODS
Service evaluation. pwMS using the MS service at Barts Health NHS Trust were sent questionnaires to report symptoms following vaccination.
RESULTS
RESULTS
Thirty-three responses were returned, 29/33 pwMS received a first dose of AstraZeneca vaccine, the remaining four received a first dose of BioNTech/Pfizer vaccine. All but two patients (94%) reported any symptoms including a sore arm (70%), flu-like symptoms (64%), fever (21%), fatigue (27%), and headache (21%). In more than 2/3 patients, symptoms lasted up to 48 hours, and with the exception of two pwMS reporting symptom duration of 10 and 12 days, respectively, symptoms in the remainder resolved within seven days. No severe adverse effects occurred.
CONCLUSIONS
CONCLUSIONS
pwMS report transient symptoms following AstraZeneca vaccination, characteristics of which were similar to those reported in the non-MS population. Symptoms may be more pronounced in pwMS due to the temperature-dependent delay in impulse propagation (Uhthoff's phenomenon) due to demyelination.
Identifiants
pubmed: 34049216
pii: S2211-0348(21)00295-9
doi: 10.1016/j.msard.2021.103028
pmc: PMC8129799
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
103028Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
BMJ. 2020 Apr 28;369:m1626
pubmed: 32345591
Clin Exp Immunol. 2020 Nov;202(2):149-161
pubmed: 32671831
N Engl J Med. 2021 May 20;384(20):1964-1965
pubmed: 33852795
Pflugers Arch. 2015 Nov;467(11):2337-49
pubmed: 25724933
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Lancet. 2020 May 16;395(10236):1527-1529
pubmed: 32353328
Pract Neurol. 2020 Dec;20(6):435-445
pubmed: 32632038
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362